Arnuity Ellipta (Fluticasone Furoate Inhalation Powder) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - August 28, 2014 Category: Drugs & Pharmacology Source Type: news
FDA OKs New Once-Daily Asthma Treatment
The FDA has approved Arnuity Ellipta (fluticasone furoate inhalation powder), an inhaled steroid taken once a day to prevent asthma symptoms in people 12 and older, drugmaker GlaxoSmithKline says. (Source: WebMD Health)
Source: WebMD Health - August 21, 2014 Category: Consumer Health News Source Type: news
Over-the-Counter Flonase Allergy Relief Approved
(Source: eMedicineHealth.com)
Source: eMedicineHealth.com - July 31, 2014 Category: Journals (General) Source Type: news
fluticasone (nasal inhaler-spray, Flonase, Veramyst)
Title: fluticasone (nasal inhaler-spray, Flonase, Veramyst)Category: MedicationsCreated: 3/26/1998 2:30:00 PMLast Editorial Review: 7/31/2014 12:00:00 AM (Source: MedicineNet Allergies General)
Source: MedicineNet Allergies General - July 31, 2014 Category: Allergy & Immunology Source Type: news
Over-the-Counter Flonase Allergy Relief Approved
Title: Over-the-Counter Flonase Allergy Relief ApprovedCategory: Health NewsCreated: 7/29/2014 11:00:00 AMLast Editorial Review: 7/29/2014 12:00:00 AM (Source: MedicineNet Allergies General)
Source: MedicineNet Allergies General - July 29, 2014 Category: Allergy & Immunology Source Type: news
Over-the-Counter Flonase Allergy Relief Approved
The FDA has approved over-the-counter Flonase Allergy Relief, or fluticasone propionate 50 mcg nasal spray, for treatment of hay fever or upper respiratory allergies, its maker GlaxoSmithKline announced. (Source: WebMD Health)
Source: WebMD Health - July 28, 2014 Category: Consumer Health News Source Type: news
FDA Clears OTC Flonase Nasal Spray for Allergy Relief FDA Clears OTC Flonase Nasal Spray for Allergy Relief
Fluticasone propionate 50 mcg nasal spray is the first and only OTC nasal spray for hay fever and upper respiratory allergies. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 26, 2014 Category: Consumer Health News Tags: Allergy & Clinical Immunology News Source Type: news
Flonase Goes OTC
(MedPage Today) -- The FDA has approved over-the-counter sales for Flonase (fluticasone propionate), the nasal spray for allergies, its manufacturer said. (Source: MedPage Today Allergy)
Source: MedPage Today Allergy - July 25, 2014 Category: Allergy & Immunology Source Type: news
FDA approves Flonase allergy relief for sale over-the-counter in the United States
No. 1 prescribed allergy treatment ingredient1 to be available OTC (Source: GSK news)
Source: GSK news - July 24, 2014 Category: Pharmaceuticals Source Type: news
High-dose fluticasone effective against eosinophilic esophagitis, study shows
High doses of the corticosteroid fluticasone propionate safely and effectively induce remission in many people with eosinophilic esophagitis, a chronic inflammatory disease of the esophagus characterized by high levels of white blood cells called eosinophils, research shows. However, some trial participants in the study did not respond to fluticasone even after six months of high-dose treatments, providing evidence that certain people with eosinophilic esophagitis are steroid-resistant. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - July 18, 2014 Category: Science Source Type: news
High-dose fluticasone effective against eosinophilic esophagitis
(NIH/National Institute of Allergy and Infectious Diseases) Results from a clinical trial show that high doses of the corticosteroid fluticasone propionate safely and effectively induce remission in many people with eosinophilic esophagitis, a chronic inflammatory disease of the esophagus characterized by high levels of white blood cells called eosinophils. However, some trial participants did not respond to fluticasone even after six months of high-dose treatments, providing evidence that certain people with eosinophilic esophagitis are steroid-resistant. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 18, 2014 Category: Global & Universal Source Type: news
Steroid asthma inhalers restrict children’s growth
Conclusion
This systematic review has found that inhaled corticosteroid drugs suppress growth in children with persistent asthma who take them regularly, during the first year of treatment.
This was high quality, well-conducted research, and its conclusions are likely to be reliable.
While the results are likely to worry parents, uncontrolled asthma can restrict a child’s activities and lower their quality of life. In severe cases, it can lead to life-threatening asthma attacks.
Even low-grade, persistent symptoms can lead to fatigue, underperformance or absence from school as well as psychological problems, includ...
Source: NHS News Feed - July 17, 2014 Category: Consumer Health News Tags: Heart/lungs Medication Source Type: news
GSK/Theravance Seek to Expand Marketing of COPD Inhaler
The companies seek approval in the U.S. to expand their COPD inhaler Breo Ellipta (fluticasone furoate/vilanterol) for patients with asthma (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - July 2, 2014 Category: Pharmaceuticals Source Type: news
GSK and Theravance submit supplemental new drug application to FDA for asthma treatment
GlaxoSmithKline (GSK) and Theravance have submitted a supplemental new drug application (sNDA) to the US Food and Drug Administration (FDA) for a fixed dose combination of fluticasone furoate and vilanterol (FF/VI) as a once-daily treatment for asthm… (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - June 30, 2014 Category: Pharmaceuticals Source Type: news
GSK and Theravance announce submission to US regulatory authorities for fluticasone furoate/vilanterol in asthma
GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced the submission of a supplemental New Drug Application (sNDA) to the US Food and Drug Administration (FDA). (Source: GSK news)
Source: GSK news - June 30, 2014 Category: Pharmaceuticals Source Type: news
